CrystalGenomics Obtains Mexican Patent for Anticancer Drug 'Ivaltinostat'

[Asia Economy Reporter Lee Gwan-joo] CrystalGenomics announced on the 23rd that its pancreatic cancer drug candidate 'Ivaltinostat' has obtained a patent in Mexico.

The patent is titled "Pharmaceutically acceptable salts of alkylcarbamoyl naphthalenyl oxy octenoyl hydroxamic acid or its derivatives and their manufacturing methods."

This salt patent is the fifth patent obtained following Korea, Australia, Russia, and Japan, and it improves moisture stability while maintaining characteristics such as efficacy and effective dosage of Ivaltinostat, enabling commercial production.

Through this, the company explained that it facilitates the raw material manufacturing of Ivaltinostat, improves solubility, enhances the physicochemical stability of the raw material itself, and allows powderization, which can significantly improve profitability upon commercialization. They also added that development into various formulations, including oral formulations that can improve patient compliance in addition to the existing injectable form, is possible.

A CrystalGenomics official stated, "By registering the patent in Mexico, we will continuously expand the patent rights of Ivaltinostat by country and broaden the possibility of licensing technology exports according to clinical development."

This content was produced with the assistance of AI translation services.